https://www.openbell.ai/ 2026-10-19T12:28:47.051Z hourly 1.0 https://www.openbell.ai/support 2026-10-19T12:28:47.051Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-19T12:28:47.051Z monthly 0.5 https://www.openbell.ai/terms 2026-10-19T12:28:47.051Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-19T12:28:47.051Z hourly 0.8 https://www.openbell.ai/news/NRSN:1792412890779 2026-10-19T12:28:10.779Z daily 0.9 https://cdn.brandfetch.io/NRSN/w/400/h/400?c=1idopYfmtR7ZKg8QMud NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib NeuroSense Therapeutics has filed a U.S. patent application for methods to treat traumatic brain injury (TBI) and related central nervous system injuries using a combination of ciprofloxacin and celecoxib. The patent, if granted, could provide protection until 2047 and aims to address the significant unmet medical need for disease-modifying therapies for TBI. The company is also exploring future TBI-focused research initiatives while maintaining ALS as its primary development priority. https://www.openbell.ai/news/ZONE:1792412610830 2026-10-19T12:23:30.830Z daily 0.9 https://cdn.brandfetch.io/ZONE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zone Frontier Approves 1-For-60 Reverse Stock, Effective October 30, 2026 Zone Frontier Inc. has announced a 1-for-60 reverse stock split, effective at 12:01 a.m. ET on October 30, 2026. This action aims to increase the per-share trading price and support its continued listing on the NYSE American, where trading will resume under the symbol 'ZONE' on a split-adjusted basis. The number of outstanding shares will decrease from approximately 508.9 million to about 8.5 million, with authorized shares reduced from 6.94 billion to 115.7 million, while the par value remains at $0.0001. https://www.openbell.ai/news/TTMI:1792412581172 2026-10-19T12:23:01.172Z daily 0.9 https://cdn.brandfetch.io/TTMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud TTM Technologies Agrees To Acquire Ophir Optics Operations From MKS For ~$650M In Cash TTM Technologies, Inc. (NASDAQ: TTMI) has announced a definitive agreement to acquire the Ophir Optics business from MKS Inc. (NASDAQ: MKSI) for approximately $650 million in cash. Ophir Optics specializes in high-precision infrared thermal imaging and laser optics solutions, catering to defense, security, and industrial applications. The transaction is subject to customary closing adjustments. https://www.openbell.ai/news/NVDA:1792412570392 2026-10-19T12:22:50.392Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Santander Builds AI Capabilities That Improve Performance And Lower Costs Using NVIDIA AI Infrastructure Santander has enhanced its artificial intelligence capabilities by utilizing NVIDIA's AI infrastructure, aiming to improve operational performance and reduce costs. This strategic move is expected to bolster the bank's efficiency and competitiveness in the financial sector. The collaboration with NVIDIA aligns with Santander's ongoing efforts to integrate advanced technologies into its services. https://www.openbell.ai/news/NVDA:1792412544046 2026-10-19T12:22:24.046Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Siemens Partners With NVIDIA To Advance AI-Driven, Autonomous Factories Siemens has announced a partnership with NVIDIA to develop AI-driven autonomous factories, aiming to enhance manufacturing efficiency and innovation. This collaboration will leverage NVIDIA's AI technology and Siemens' industrial expertise to create smarter production environments. The partnership is expected to accelerate the adoption of AI in the manufacturing sector, potentially impacting stock performance for both companies. https://www.openbell.ai/news/JPM:1792412412914 2026-10-19T12:20:12.914Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/4-Stocks-JPMorgan-Is-Betting-Big-On-For-.jpg?width=250&height=187 JPMorgan Taps Ethereum for JPM Coin as Tokenization Race Heats Up JPMorgan Chase & Co (NYSE: JPM) has expanded its JPM Coin (JPMD) to the Ethereum blockchain, enabling institutional clients to conduct blockchain-based payments and settle tokenized asset transactions continuously. This move follows the launch of two tokenized money-market funds on Ethereum in late 2025 and early 2026, and the bank's Kinexys platform has processed over $4 trillion in transactions. The expansion is expected to enhance Ethereum's role in institutional payments, as the network currently holds around $50 billion in DeFi assets. https://www.openbell.ai/news/NBIS:1792412282449 2026-10-19T12:18:02.449Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Nebius-Group.jpg?width=250&height=187 Why Is Nebius Group Stock Surging Monday? Nebius Group N.V. (NASDAQ: NBIS) stock rose 7.10% to $177.22 in premarket trading on Monday, recovering from a 25% decline the previous week, driven by renewed analyst support and a positive sentiment towards technology stocks. Truist maintained a Buy rating with a price target of $355, arguing that concerns from a failed IPO do not reflect broader weaknesses in the neocloud sector. Despite the rebound, Nebius shares remain below key moving averages, indicating ongoing selling pressure and competition challenges in the AI infrastructure market. https://www.openbell.ai/news/MAZE:1792412194100 2026-10-19T12:16:34.100Z daily 0.9 https://cdn.brandfetch.io/MAZE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75 Canaccord Genuity analyst Whitney Ijem has initiated coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating. The firm has set a price target of $75 for the stock. https://www.openbell.ai/news/DAIC:1792412141979 2026-10-19T12:15:41.979Z daily 0.9 https://cdn.brandfetch.io/DAIC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Dot Ai Subsidiary Envoy Expands New Jersey EV Car-Sharing Program, Offering No-Cost Service To Residential Properties Through $8.1M Grant Initiative Envoy, a subsidiary of Dot Ai (NASDAQ: DAIC), is expanding its electric vehicle car-sharing program in New Jersey, supported by an $8.1 million grant initiative. The program allows residential property owners to nominate locations for the service, providing residents access to shared electric vehicles at no cost to the properties. Envoy will manage the vehicles, including insurance and maintenance, offering a convenient transportation option for residents without the burdens of car ownership. https://www.openbell.ai/news/QNRX:1792412080814 2026-10-19T12:14:40.814Z daily 0.9 https://cdn.brandfetch.io/QNRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Whitney Ijem has initiated coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating. The firm has set a price target of $18 for the stock. https://www.openbell.ai/news/SNES:1792411861796 2026-10-19T12:11:01.796Z daily 0.9 https://cdn.brandfetch.io/SNES/w/400/h/400?c=1idopYfmtR7ZKg8QMud SenesTech Announced Results From A Pilot Of Evolve; Reports Over A 12-Month Period, Standardized Tracking-Tunnel Surveys Documented An 88% Reduction In Average Rat Activity Intensity And An 82% Reduction In The Proportion Of Monitoring Locations With Detectable Rat Activity SenesTech, Inc. (NASDAQ: SNES) reported significant results from a pilot program of its Evolve® Rat Birth Control™ in Chicago, showing an 88% reduction in average rat activity intensity and an 82% decrease in monitoring locations with detectable rat activity over a 12-month period. The company also announced preliminary record third-quarter 2026 revenue of approximately $1.1 million, marking a 40% sequential increase and a 55% year-over-year growth. Additionally, rodent-related 311 calls in the deployment area fell by 36%, while citywide calls increased by less than 1% during the same timeframe. https://www.openbell.ai/news/RDHL:1792411853209 2026-10-19T12:10:53.209Z daily 0.9 https://cdn.brandfetch.io/RDHL/w/400/h/400?c=1idopYfmtR7ZKg8QMud RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively RedHill Biopharma Ltd. announced that its partner, the University of Oklahoma, has secured $2.9 million in funding from the National Cancer Institute to conduct clinical trials on the efficacy of RedHill's opaganib following CAR T-cell therapy. The funding will support two phases of trials, with Phase 1b enrolling up to 18 patients to assess safety and dosage, and Phase 2 enrolling an additional 21 patients to gather preliminary effectiveness data. This initiative marks a significant step as CAR T cells will be manufactured on the OU campus, potentially reducing costs and time for treatment. https://www.openbell.ai/news/QTEX:1792411787437 2026-10-19T12:09:47.437Z daily 0.9 https://cdn.brandfetch.io/QTEX/w/400/h/400?c=1idopYfmtR7ZKg8QMud QTREX Quantum Regains Nasdaq Compliance QTREX Quantum Ltd. (Nasdaq: QTEX) has regained compliance with Nasdaq's minimum bid price requirement as of October 16, 2026. The company achieved this by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days from October 2 to October 15, 2026. As a result, QTREX's ordinary shares will continue to be listed and traded on The Nasdaq Capital Market. https://www.openbell.ai/news/AVBP:1792411769836 2026-10-19T12:09:29.836Z daily 0.9 https://cdn.brandfetch.io/AVBP/w/400/h/400?c=1idopYfmtR7ZKg8QMud ArriVent Publishes FURTHER Phase 1b Results Of Firmonertinib In Cancer Cell openbell Financial News https://www.openbell.ai/news/MNKD:1792411759811 2026-10-19T12:09:19.811Z daily 0.9 https://cdn.brandfetch.io/MNKD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10 Chardan Capital analyst Andreas Argyrides has initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating. The firm has set a price target of $10 for the company's stock. https://www.openbell.ai/news/JNJ:1792411730725 2026-10-19T12:08:50.725Z daily 0.9 https://cdn.brandfetch.io/JNJ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease Johnson & Johnson (NYSE: JNJ) announced one-year results from the Phase 3 FUZION study, revealing that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks. The remission rate increased from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group. These results support the efficacy of TREMFYA in treating challenging manifestations of Crohn's disease and were presented at the 2026 United European Gastroenterology Week. https://www.openbell.ai/news/BHC:1792411722945 2026-10-19T12:08:42.945Z daily 0.9 https://cdn.brandfetch.io/BHC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans Bausch Health Canada has announced that its product PrOKEDI 75 mg and 100 mg is now publicly reimbursed in seven provinces, including Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia, and Prince Edward Island, as well as through several federal drug plans. PrOKEDI is a prolonged-release injectable suspension of risperidone used for treating schizophrenia in adults, designed for a four-week dosing interval without the need for oral supplementation. https://www.openbell.ai/news/BIVI:1792411696703 2026-10-19T12:08:16.703Z daily 0.9 https://cdn.brandfetch.io/BIVI/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association BioVie Inc. (NASDAQ: BIVI) presented results from its Phase 2 ADDRESS-LC study evaluating bezisterim (NE3107) for Long COVID at the 151st Annual Meeting of the American Neurological Association held from October 17–20, 2026, in San Diego, California. The study's abstract was published in the Annals of Neurology, highlighting the company's ongoing efforts in developing innovative therapies for neurological diseases. https://www.openbell.ai/news/ARGX:1792411673848 2026-10-19T12:07:53.848Z daily 0.9 https://cdn.brandfetch.io/ARGX/w/400/h/400?c=1idopYfmtR7ZKg8QMud argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 argenx SE will present new data from its Phase 3 study of VYVGART Hytrulo, an FcRn blocker, focusing on autoimmune myositis, specifically IMNM and DM, at the ACR Convergence 2026. Results from the ALKIVIA study indicate that efgartigimod provides significant patient improvements as early as Week 4, sustained through 52 weeks. The late-breaking presentation is scheduled for November 11, 2026, in Orlando, Florida. https://www.openbell.ai/news/ACHR:1792411574093 2026-10-19T12:06:14.093Z daily 0.9 https://cdn.brandfetch.io/ACHR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Archer Completes Electric Air Taxi Flights Over San Francisco Bay Archer Aviation has successfully completed electric air taxi flights over San Francisco Bay as part of its No Roads Tour. The Midnight air taxi is now heading south to Los Angeles for further demonstrations. This marks a significant milestone in Archer's efforts to advance urban air mobility. https://www.openbell.ai/news/CLDI:1792411566775 2026-10-19T12:06:06.775Z daily 0.9 https://cdn.brandfetch.io/CLDI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings Calidi Biotherapeutics, Inc. (NYSE: CLDI) will present preclinical data on its CLD-401 and CLD-501 programs at the ESMO Congress 2026 in Madrid, showcasing findings on tumor eradication and antitumor activity. The CLD-401 program demonstrated high rates of complete tumor eradication in EMT6 breast cancer models and retained antitumor activity through various delivery methods. The CLD-501 program, part of the in situ T-cell engager platform, showed effective T cell-mediated cytotoxicity without compromising IL-15 superagonist expression. The company is also seeking strategic partnerships to enhance the clinical development of its RedTail platform. https://www.openbell.ai/news/AAME:1792411538094 2026-10-19T12:05:38.094Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 11 Financials Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, Atlantic American (NASDAQ:AAME) saw a significant stock increase of 44.6%, reaching $1.52, with a market cap of $21.6 million following its Q4 earnings report. MDB Capital Holdings (NASDAQ:MDBH) rose by 18.07% to $2.09, while Dominari Holdings (NASDAQ:DOMH) increased by 10.71% to $2.17. Conversely, House of Doge (NASDAQ:HODO) experienced a sharp decline of 26.5%, dropping to $0.07, with a market cap of $6.0 million. https://www.openbell.ai/news/IRON:1792411537900 2026-10-19T12:05:37.900Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=250&height=187 12 Health Care Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, Disc Medicine (NASDAQ: IRON) saw a significant increase of 50.4%, reaching $85.51, with a market cap of $2.1 billion. Other notable gainers included DataMEDS AI (NASDAQ: MEDS) up 19.77% to $3.15, and Virax Biolabs Group (NASDAQ: VRAX) rising 17.24% to $1.7. Conversely, EyePoint (NASDAQ: EYPT) experienced a drastic decline of 80%, dropping to $0.6, with a market cap of $270.7 million. https://www.openbell.ai/news/ZONE:1792411537716 2026-10-19T12:05:37.716Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Industrials Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, Zone Frontier (AMEX: ZONE) saw a significant increase of 26.1%, reaching $0.12, with a market value of $60.5 million. Other notable gainers included OpenWorld (NASDAQ: OPNW) up 9.02% to $2.9 and EquipmentShare.com (NASDAQ: EQPT) rising 8.79% to $14.78, with market caps of $38.4 million and $3.6 billion respectively. Conversely, Robin Energy (NASDAQ: RBNE) experienced a sharp decline of 36.7% to $0.49, bringing its market cap down to $2.5 million. https://www.openbell.ai/news/AMPGZ:1792411537440 2026-10-19T12:05:37.440Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Information Technology Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, Amplitech Group, Inc. (NASDAQ: AMPGZ) shares rose by 31.7% to $0.13. Other notable gainers included 3 E Network (NASDAQ: MASK) with a 30.54% increase to $1.05, and Exascale Labs Holdings (NASDAQ: XLAB) which saw an 18.8% rise to $2.79. Conversely, Sangrix (NASDAQ: SGRX) experienced a significant decline of 32.8% to $0.58. https://www.openbell.ai/news/IMMP:1792411522792 2026-10-19T12:05:22.792Z daily 0.9 https://cdn.brandfetch.io/IMMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Immutep's Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026 Immutep's abstract on IMP761 has been accepted for a late-breaking poster presentation at ACR Convergence 2026. The presentation will showcase data from the first-in-human Phase I study of IMP761, which is a first-in-class LAG-3 agonist antibody tested in healthy volunteers. https://www.openbell.ai/news/SGP:1792411467477 2026-10-19T12:04:27.477Z daily 0.9 https://cdn.brandfetch.io/SGP/w/400/h/400?c=1idopYfmtR7ZKg8QMud SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops SpyGlass Pharma, Inc. (Nasdaq: SGP) announced positive results from a 4-year first-in-human trial of its Bimatoprost Drug Pad-IOL System for treating mild-to-moderate open angle glaucoma. The trial showed a 37% reduction in mean intraocular pressure (IOP) from 25.1 mmHg at baseline to 15.9 mmHg, with 86% of participants remaining off all topical IOP-lowering drops. Additionally, 90% of patients maintained a best-corrected distance visual acuity of ≥20/25, and no product-related adverse events were reported. https://www.openbell.ai/news/CLNN:1792411433168 2026-10-19T12:03:53.168Z daily 0.9 https://cdn.brandfetch.io/CLNN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Clene Submits New Drug Application To FDA For Accelerated Approvla Of CNM-Au8 Clene has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for its drug CNM-Au8. The application is based on data related to neurofilament light chain biomarkers and clinical outcomes. This move is significant for the company's growth strategy and potential market impact. https://www.openbell.ai/news/SLE:1792411334314 2026-10-19T12:02:14.314Z daily 0.9 https://cdn.brandfetch.io/SLE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Super League Enterprise Shareholders Approve Proposals For Investment In Metaplanet Super League Enterprise, Inc. (Nasdaq: SLE) announced that its shareholders approved all proposals at the 2026 Annual Meeting, including a strategic investment from Metaplanet, Inc. (TSE: 3350). This investment is part of Super League's ongoing efforts to enhance its business strategy. https://www.openbell.ai/news/URGN:1792411311430 2026-10-19T12:01:51.430Z daily 0.9 https://cdn.brandfetch.io/URGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Accepts UroGen Pharma's New Drug Application For UGN-103 openbell Financial News https://www.openbell.ai/news/BDMD:1792411301963 2026-10-19T12:01:41.963Z daily 0.9 https://cdn.brandfetch.io/BDMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Baird Medical Announces Additional Medical Device Registrations In Vietnam And Preliminary Regulatory Approval In Egypt Baird Medical has received Class C medical device registration certificates for several products in Vietnam, including its microwave ablation portfolio, which will enhance its market presence in Southeast Asia. Additionally, the Egyptian Drug Authority granted preliminary approval for the BD-GT Microwave Ablation System, marking progress towards regulatory approval in Egypt. These developments are part of Baird Medical's strategy to expand internationally while also focusing on strengthening its commercial presence in the U.S. following FDA clearance in November 2023. https://www.openbell.ai/news/GPN:1792411297003 2026-10-19T12:01:37.003Z daily 0.9 https://cdn.brandfetch.io/GPN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Upgrades Global Payments to Overweight, Announces $105 Price Target Keybanc analyst Andrew Schmidt has upgraded Global Payments (NYSE: GPN) from Sector Weight to Overweight, setting a price target of $105 for the stock. This upgrade indicates a positive outlook for the company's performance in the market. https://www.openbell.ai/news/SLN:1792411271368 2026-10-19T12:01:11.368Z daily 0.9 https://cdn.brandfetch.io/SLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merck KGaA Agrees To Acquire Silence Therapeutics For $20 Per ADS In Cash Merck KGaA has agreed to acquire Silence Therapeutics plc for $20 per ADS in cash, equating to $6.6667 per ordinary share. This acquisition values Silence Therapeutics at approximately $1.1 billion in enterprise value and $1.3 billion in equity value, representing an 82% premium over its 30-day average stock price of $10.99 prior to the announcement. The transaction is contingent upon customary closing conditions. https://www.openbell.ai/news/BTCUSD:1792411259000 2026-10-19T12:00:59.000Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Cryptocurrency-Coins-Displaying-XRP--Sol.jpg?width=250&height=187 Bitcoin, Ethereum, XRP Face Rebound From ‘Black Monday’ Fears Bitcoin (BTC) rose above $82,000 on Monday, recovering from fears linked to the anniversary of the 1987 Black Monday crash. Despite social media chatter warning of potential market troubles due to factors like high oil prices and rising bond yields, Bitcoin closed up nearly 1% on Sunday. Ethereum (ETH) and Solana (SOL) also saw gains of over 4%, benefiting from a broader recovery in risk appetite as Brent crude prices fell. Analysts suggest that Bitcoin needs to maintain levels above $81,000 to confirm a continued upward trend. https://www.openbell.ai/news/AIIO:1792411194373 2026-10-19T11:59:54.373Z daily 0.9 https://cdn.brandfetch.io/AIIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Robo.ai shares are trading lower after the company announced a 1-for-25 reverse stock split. openbell Financial News https://www.openbell.ai/news/MEDS:1792411124138 2026-10-19T11:58:44.138Z daily 0.9 https://cdn.brandfetch.io/MEDS/w/400/h/400?c=1idopYfmtR7ZKg8QMud DataMeds AI shares are trading higher after the company announced it entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI openbell Financial News https://www.openbell.ai/news/SLN:1792410900388 2026-10-19T11:55:00.388Z daily 0.9 https://cdn.brandfetch.io/SLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://www.openbell.ai/news/MASK:1792410877274 2026-10-19T11:54:37.274Z daily 0.9 https://cdn.brandfetch.io/MASK/w/400/h/400?c=1idopYfmtR7ZKg8QMud 3 E Network Technology Group's Finland Subsidiary Inks 9 MVA Power Distribution Network Connection Deal For Mikkeli AI Compute Center in Finland 3 E Network Technology Group Limited (NASDAQ: MASK) announced that its Finland subsidiary, Aurora Core Technology Oy, has signed a power distribution network connection agreement with Järvi-Suomen Energia Oy on October 13, 2026. This agreement is a significant infrastructure milestone for the Mikkeli AI compute center project, enabling the deployment of high-performance AI compute clusters. The deal supports the company's goal of advancing its 'Multi-Megawatt Green AI Compute Architecture.' https://www.openbell.ai/news/SAFX:1792410779857 2026-10-19T11:52:59.857Z daily 0.9 https://cdn.brandfetch.io/SAFX/w/400/h/400?c=1idopYfmtR7ZKg8QMud XCF Global shares are trading higher after the company announced it completed its business combination with Southern Energy Renewables and DevvStream. openbell Financial News https://www.openbell.ai/news/EYPT:1792410612187 2026-10-19T11:50:12.187Z daily 0.9 https://cdn.brandfetch.io/EYPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud EyePoint shares are trading lower after the company announced topline results from LUCIA did not achieve its primary endpoint. openbell Financial News https://www.openbell.ai/news/CDNL:1792410462286 2026-10-19T11:47:42.286Z daily 0.9 https://cdn.brandfetch.io/CDNL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cardinal Infrastructure Group shares are trading higher after the company announced that it has entered into an amendment to its previously announced agreement to acquire Hughes Brothers Construction. openbell Financial News https://www.openbell.ai/news/AIB:1792410401851 2026-10-19T11:46:41.851Z daily 0.9 https://cdn.brandfetch.io/AIB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Freedom Capital Markets Initiates Coverage On AIB Data Centers with Buy Rating, Announces Price Target of $2.5 Freedom Capital Markets has initiated coverage on AIB Data Centers (AMEX:AIB) with a Buy rating. The analyst, Paul Meeks, has set a price target of $2.5 for the stock. https://www.openbell.ai/news/EQPT:1792410262542 2026-10-19T11:44:22.542Z daily 0.9 https://cdn.brandfetch.io/EQPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud EquipmentShare.com shares are trading higher after the company announced it raised its FY26 sales guidance above estimates. openbell Financial News https://www.openbell.ai/news/CLF:1792410227353 2026-10-19T11:43:47.353Z daily 0.9 https://cdn.brandfetch.io/CLF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cleveland-Cliffs shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results. openbell Financial News https://www.openbell.ai/news/CRWV:1792410204861 2026-10-19T11:43:24.861Z daily 0.9 https://cdn.brandfetch.io/CRWV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Upgrades CoreWeave to Buy, Announces $106 Price Target Goldman Sachs has upgraded CoreWeave (NASDAQ: CRWV) from a Neutral rating to a Buy rating. The firm has set a price target of $106 for the stock, indicating a positive outlook for the company's performance. https://www.openbell.ai/news/IRON:1792410190847 2026-10-19T11:43:10.847Z daily 0.9 https://cdn.brandfetch.io/IRON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Disc Medicine shares are trading higher after the company announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria, including X-linked protoporphyria met all its primary and secondary endpoints. openbell Financial News https://www.openbell.ai/news/USO:1792410116573 2026-10-19T11:41:56.573Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Iran’s Main Oil Terminals Remain Empty as US Blockade Bites' - Bloomberg Iran's main oil terminals are experiencing significant emptiness due to the ongoing US blockade, severely impacting the country's oil exports. The blockade has led to a drastic reduction in oil shipments, with reports indicating that Iran's oil production has plummeted to its lowest levels in years. This situation is likely to affect global oil markets and pricing, particularly for crude oil derivatives. https://www.openbell.ai/news/CHRD:1792410025121 2026-10-19T11:40:25.121Z daily 0.9 https://cdn.brandfetch.io/CHRD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chord Energy Reports Preliminary Q3 Total Production 290.5K–290.9K Boe/d Chord Energy reported preliminary total production for Q3 at 290.5K–290.9K Boe/d, exceeding guidance across oil, natural gas, and NGLs. The company executed $205MM in share repurchases at an average price of $135.74/share during Q3 and an additional $44.3MM in Q4. Additionally, Chord announced the divestiture of non-operated Marcellus assets for $550MM and reported cash and cash equivalents of $804.7MM against total debt of $1,482.2MM as of September 30, 2026. https://www.openbell.ai/news/GM:1792410008659 2026-10-19T11:40:08.659Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/GM-General-Motors.jpg?width=250&height=187 How To Earn $500 A Month From General Motors Stock Ahead Of Q3 Earnings General Motors Co. (NYSE: GM) is set to release its Q3 earnings report on October 20, with analysts expecting earnings of $3.60 per share and quarterly revenue of $48.6 billion, slightly up from last year's $48.59 billion. GM has consistently exceeded EPS estimates for the last 12 quarters. The company currently offers an annual dividend yield of 0.86%, with a quarterly dividend of 18 cents per share, requiring approximately $699,639 in investment to generate $500 monthly in dividends. GM shares closed at $83.96, reflecting a 0.4% increase. https://www.openbell.ai/news/ATNM:1792409847474 2026-10-19T11:37:27.474Z daily 0.9 https://cdn.brandfetch.io/ATNM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21 Actinium Pharmaceuticals will present data and preclinical results for its drug ATNM-400 at the Congress of the European Association of Nuclear Medicine from October 17-21, 2026. The Phase 1 study will focus on metastatic castration-resistant prostate cancer, while preclinical studies will explore its application in KRAS- and ALK-driven non-small cell lung cancer. ATNM-400 employs a HER3-targeted alpha radiotherapy approach, indicating potential use as both a monotherapy and in combination with existing treatments across various solid tumors.